Clinical trials: Mouth Breathing
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale.
- Trial name
- REFALS (NCT03505021)
- Testing
- Levosimendan
- Where
- 104 sites in United States, Australia and 12 more
- Volunteers
- 496 people
- Sponsor
- Orion Corporation, Orion Pharma
Chronic Obstructive Pulmonary Disease (COPD)
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)
- Trial name
- NCT01054170
- Testing
- AZD9668
- Where
- 9 sites in Canada, Denmark and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Single-ventricle
Simple Non-invasive Breathing Device to Improve Pulmonary Flow Pusatility in Single Ventricle Post Fontan
This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will…
- Trial name
- NCT05634226
- Testing
- Hands-free oral-positive pressure device (oPEP)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Tarek Alsaied
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in…
- Trial name
- NCT02296138
- Testing
- olodaterol, tiotropium
- Where
- 818 sites in United States, Argentina and 49 more
- Volunteers
- 7,903 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
- Trial name
- NCT00703391
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Respiratory Depression, Respiratory Failure
Assessment of a Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes
Assessment of AnchorFast Guard Oral Endotracheal Tube Fastener on Patients Intubated with Oral Endotracheal Tubes with Subglottic Suction
- Conditions
- Respiratory Depression, Respiratory Failure, Ventilatory Depression
- Trial name
- NCT02760927
- Testing
- Endotracheal Tube Fastener
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Hollister Incorporated
Xerostomia Following Radiotherapy, Xerostomia Following in Neck or Head After Cancer Surgery
Does Craniosacraltherapy Combined With Exercises That Focuses om Respiration and Posture in the Upper Body Have an Effect on Xerostomia and Other Late Sequelae on People Who Has Been Suffering From Cancer in Mouth and Throat?
The current study aims to assess the efficacy of manual treatment with craniosacral therapy of fascial tissue in throat, neck, cranial and mouth region, on radiation and/or surgery-induced salivary gland hypofunction and…
- Conditions
- Xerostomia Following Radiotherapy, Xerostomia Following in Neck or Head After Cancer Surgery, Other Late Sequelae Following Radiotherapy and Cancer Surgery in Neck or Head
- Trial name
- NCT05882890
- Testing
- Craniosacral Therapy, Exercices Targeting Upper Posture and Respiration
- Where
- 2 sites in Denmark
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Cathrine Rahbek
Obstructive Sleep Apnea
Trial on Oral Appliance Design for Improving Upper Airway Function and Sleep Quality
This study will compare the effectiveness of the two leading oral appliances (OAs) designs for the treatment of severe obstructive sleep apnea in overweight adults.
- Trial name
- NCT03219034
- Testing
- oral appliance - A ; washout; oral appliance B, oral appliance - B; washout; oral appliance A
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Texas A&M University
Healthy
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Compare the acute effects and tolerability of Dihydroergotamine Mesylate (DHE) delivered by Oral Inhalation (MAP0004) versus by intravenous (IV) infusion in healthy adult volunteers.
- Trial name
- NCT01089062
- Testing
- MAP0004, IV Dihydroergotamine Mesylate (DHE)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Allergan
Primary Ciliary Dyskinesia
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
- Trial name
- CLEAN-PCD (NCT02871778)
- Testing
- VX-371, Hypertonic Saline, VX-371 + HS
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 123 people
- Sponsor
- Parion Sciences
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the Respimat® inhaler, once daily for four weeks in…
- Trial name
- NCT00720499
- Testing
- BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 141 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium…
- Trial name
- NCT01311661
- Testing
- Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily
- Where
- 36 sites in United States, Austria and 4 more
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based…
- Trial name
- NCT00437489
- Testing
- Inhaled Human Insulin (Exubera)
- Where
- 9 sites in Hong Kong, Pakistan and 2 more
- Volunteers
- 49 people
- Sponsor
- Pfizer
Unrecognized Condition
Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.
If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?
- Trial name
- NCT03766646
- Testing
- Optiflow
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Mountain Sickness
Safety Evaluation of Aminophylline and Methazolamide
This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.
- Trial name
- NCT01587027
- Testing
- Aminophylline, Methazolamide, Aminophylline and Methazolamide
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Poudre Valley Health System
Asthma
Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma
The primary objective of this study is to assess the efficacy (bronchoprotection) and safety of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the Respimat® inhaler, in patients with…
- Trial name
- NCT00928668
- Testing
- Olodaterol (BI1744CL)
- Where
- 4 sites in Canada
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Obstructive Sleep Apnea Syndrome
Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients
To study the effect of Xyrem (9 g), Xyrem (9 g) plus modafinil 200 mg administered the morning prior to Xyrem, positive control (zolpidem 10 mg), and placebo on the frequency and outcome of events of sleep-disordered breathing in…
- Trial name
- NCT00086281
- Testing
- Xyrem (X), Zolpidem (Z), Modafinil (M)
- Where
- 2 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Jazz Pharmaceuticals
Pulmonary Hypertension
Effect of Inhaled Albuterol in Pulmonary Hypertension
The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient…
- Trial name
- NCT03270332
- Testing
- Albuterol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Miami
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01696058
- Testing
- Tiotropium, Olodaterol
- Where
- 94 sites in United States
- Volunteers
- 1,137 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00796653
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 98 sites in Argentina, Brazil and 18 more
- Volunteers
- 937 people
- Sponsor
- Boehringer Ingelheim